Deniz Can Guven, Medical Oncologist at , shared on X/Twitter:
”The 1st-in-human phase 1 study on arginase inhibitor INCB001158 is out on BMJ Oncology.
Led by my great mentor Aung Naing.
Tested a strong preclinical hypothesis:
- A total of 107 patients.
- Monotherapy or with pembrolizumab.
- + Tolerable with fatigue and GI adverse events.
- – Very limited efficacy.
Need more data on the role of arginine metabolism in TME immunosuppression. Kudos to all authors.”
Read further.
Source: Deniz Can Guven/X